Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

75%

6 of 8 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 1

6(60.0%)

Phase 2

2(20.0%)

Phase 3

2(20.0%)

10Total

Phase 1(6)

Phase 2(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT05111002Phase 1Terminated

Lefamulin for M. Genitalium Treatment Failures

Role: collaborator

NCT05225805Phase 1Completed

Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis

Role: lead

NCT03709914Phase 1Unknown

PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)

Role: lead

NCT01119105Phase 2Completed

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Role: lead

NCT02559310Phase 3Completed

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

Role: lead

NCT02813694Phase 3Completed

Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia

Role: lead

NCT02753946Phase 2Completed

Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

Role: lead

NCT03709927Phase 1Completed

4-way Crossover QT Evaluation in Healthy Subjects

Role: lead

NCT03131141Phase 1Completed

A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781

Role: lead

NCT02557789Phase 1Completed

Bioavailability and Pharmacokinetics of Lefamulin When Administered to Fed and Fasted Healthy Subjects

Role: lead

All 10 trials loaded